About the Company
NEMUS Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids. These molecules display pleiotropic activity by virtue of selectively binding to two types of cannabinoid receptors (CB1 and CB2 receptors) located throughout multiple organ systems in the body. NEMUS Bioscience Inc. is developing novel and proprietary classes of product candidates that are designed to improve therapeutic options through enhanced chemical engineering that allow drug candidates to have more predictable bioavailability and pharmacokinetics leading to optimized efficacy and safety.
NEMUS Bioscience Inc., a Nevada corporation is listed on the OTC Bulletin Board and trading under the symbol NMUS.
NEMUS Bioscience and the University of Mississippi Announce Significant Anti-MRSA Synergy Data Utilizing Proprietary Cannabinoid-Based Anti-Infective Platforms
COSTA MESA, CA–(Marketwired – Mar 22, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) and the company’s discovery and research partner, the University of Mississippi (UM), today announced that bactericidal synergy was achieved against multiple species of...
Nemus Bioscience Signs Development Agreement with Nanomerics to Advance Ocular Formulation of NB1111 for the Treatment of Glaucoma Using Proprietary Molecular Envelope Technology (MET)
COSTA MESA, CA–(Marketwired – Mar 20, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) announced that the company has signed a development agreement with Nanomerics Ltd. of the United Kingdom, to develop a topical ocular formulation of...
COSTA MESA, CA–(Marketwired – Mar 3, 2017) – NEMUS Bioscience, Inc. ( OTCQB : NMUS ) today announced that the company is moving forward with Catalent Pharma Solutions (Catalent) to advance development of a human-dosage suppository formulation of NB1222,...
Nemus Bioscience Reports Favorable Bio-distribution and Anti-Addictive Findings Versus Plant-Derived Cannabidiol (CBD) in Animal Model Studies of NB2111, an Analogue of Cannabidiol
COSTA MESA, CA / ACCESSWIRE / February 13, 2017 / NEMUS Bioscience, Inc. (NMUS) announced that the company and its research and development partner, the University of Mississippi School of Pharmacy (UM), have conducted in vitro and in vivo...